Payment overview · 2025
General Payments
$353.88
16 reported records · 9 companies
Healthcare provider profile · identity verified
Aaron Michael Evers, BSN, MS, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SALEM, OR · NPI 1689696510
Verified facts
What the public records show
CMS Open Payments records show Aaron Michael Evers, BSN, MS, FNP-C received $353.88 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.98 | 23.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.80 | 20.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.45 | 14.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.66 | 13.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.79 | 8.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.24 | 6.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.38 | 5.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $16.38 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.20 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $353.88 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.45 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.45 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $47.66 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.45 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 39 |
| Gabapentin | Gabapentin | 175 | 39 |
| Losartan Potassium | Losartan Potassium | 164 | 44 |
| Omeprazole | Omeprazole | 154 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 35 |
| Lisinopril | Lisinopril | 151 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 149 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 41 |
| Potassium Chloride | Potassium Chloride | 128 | 29 |
| Furosemide | Furosemide | 122 | 34 |
| Metformin Hcl | Metformin Hcl | 107 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 30 |
| Trazodone Hcl | Trazodone Hcl | 107 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 27 |
| Metformin Hcl Er | Metformin Hcl | 99 | 28 |
| Prednisone | Prednisone | 89 | 56 |
| Ozempic | Semaglutide | 87 | 12 |
| Buspirone Hcl | Buspirone Hcl | 76 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 18 |
| Eliquis | Apixaban | 72 | 17 |
| Tramadol Hcl | Tramadol Hcl | 69 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 16 |
| Sertraline Hcl | Sertraline Hcl | 58 | 20 |
| Mirtazapine | Mirtazapine | 54 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 11 |
| Ezetimibe | Ezetimibe | 53 | 14 |
| Allopurinol | Allopurinol | 49 | 13 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Jardiance | Empagliflozin | 46 | 13 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Alprazolam | Alprazolam | 42 | 11 |
| Cephalexin | Cephalexin | 41 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 18 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Azithromycin | Azithromycin | 37 | 30 |
| Cefuroxime | Cefuroxime Axetil | 37 | 22 |
| Celecoxib | Celecoxib | 36 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 14 |
| Lidocaine | Lidocaine | 35 | suppressed |
| Oxycontin | Oxycodone Hcl | 35 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Famotidine | Famotidine | 30 | 13 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 17 |
| Torsemide | Torsemide | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Calcitriol | Calcitriol | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $353.88 · 16 records | PFIZER INC. | ABRYSVO, COMIRNATY, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, Kerendia, MOUNJARO, NEXPLANON, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, REXULTI, The Cologuard Plus Collection Kit, Wegovy, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error